Roth Boosts PT on Sunesis Pharma (SNSS) to $15; Focus Remains on Vosaroxin
Tweet Send to a Friend
Roth Capital maintains its Buy rating on Sunesis Pharmaceuticals (Nasdaq: SNSS), but raises its price target from $12 up to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
